Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Lung Neoplasms 24Thymoma 2Sarcoma 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Adenocarcinoma of Lung 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1

Interventions

Docetaxel 7pembrolizumab 3Trastuzumab 3Radiotherapy 3Paclitaxel 3Fluorodeoxyglucose F18 3Erlotinib Hydrochloride 3Cisplatin 3Vorinostat 2Taxes 2SS1(dsFv)PE38 2Polymerase Chain Reaction 2Magnetic Resonance Spectroscopy 2Immunohistochemistry 2Gene Expression Profiling 2Filgrastim 2Cetuximab 2Biopsy 2zanidatamab 1vandetanib 1trastuzumab deruxtecan 1tipifarnib 1tanespimycin 1talactoferrin alfa 1spartalizumab 1sargramostim 1pertuzumab 1neratinib 1larotrectinib 1fluoromisonidazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × Celecoxib × Thoracic × Clear all
NCT00058006 2012-06-11

Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer

Northwestern University

Phase 2 Completed
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡